scholarly article | Q13442814 |
P50 | author | Byung-Hee Oh | Q41652919 |
Kyung Woo Park | Q89316500 | ||
Young-Bae Park | Q116485843 | ||
Seock-Won Youn | Q117234749 | ||
Myoung-Mook Lee | Q117234751 | ||
P2093 | author name string | Sung-Hwan Kim | |
Han-Mo Yang | |||
Hyo-Soo Kim | |||
Kenneth Walsh | |||
Hyun-Jeong You | |||
Soo-In Jeon | |||
P433 | issue | 3 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 301-308 | |
P577 | publication date | 2004-07-06 | |
P1433 | published in | Circulation | Q578091 |
P1476 | title | Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling | |
P478 | volume | 110 |
Q37408405 | Activation of Protein Kinase G (PKG) Reduces Neointimal Hyperplasia, Inhibits Platelet Aggregation, and Facilitates Re-endothelialization |
Q36025935 | Anti-inflammatory strategies in hypertension: focus on COX-1 and COX-2. |
Q36342136 | Aspirin enhances protective effect of fish oil against thrombosis and injury-induced vascular remodelling |
Q28258964 | Beta-catenin overexpression reduces myocardial infarct size through differential effects on cardiomyocytes and cardiac fibroblasts |
Q42059971 | COX-2 mediates PM2.5-induced apoptosis and inflammation in vascular endothelial cells |
Q35607129 | Cardiovascular biology of microsomal prostaglandin E synthase-1. |
Q36439704 | Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences? |
Q42701083 | Cardiovascular safety of celecoxib on top of dual antiplatelet therapy |
Q47372560 | Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited |
Q34021188 | Celecoxib Does Not Attenuate the Antiplatelet Effects of Aspirin and Clopidogrel in Healthy Volunteers |
Q46548988 | Celecoxib but not the combination of celecoxib+atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the rat. |
Q46699523 | Celecoxib modulates hypertrophic signalling and prevents load-induced cardiac dysfunction |
Q39819038 | Cellular membranes function as a storage compartment for celecoxib |
Q34448421 | Cyclooxygenase-2-derived prostaglandin E₂ promotes injury-induced vascular neointimal hyperplasia through the E-prostanoid 3 receptor. |
Q45288661 | Decreased glycogen synthase kinase-3 levels and activity contribute to Huntington's disease. |
Q28219713 | Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study |
Q45854165 | Effects of celecoxib on hematoma and edema volumes in primary intracerebral hemorrhage: a multicenter randomized controlled trial |
Q53384415 | Effects of celecoxib on restenosis after coronary intervention and evolution of atherosclerosis (Mini-COREA) trial: celecoxib, a double-edged sword for patients with angina. |
Q35648213 | Effects of combination therapy with celecoxib and doxycycline on neointimal hyperplasia and inflammatory biomarkers in coronary artery disease patients treated with bare metal stents |
Q35693003 | HuR mediates the synergistic effects of angiotensin II and IL-1β on vascular COX-2 expression and cell migration |
Q28200051 | Inhibition of cyclooxygenase (COX)-2 affects endothelial progenitor cell proliferation |
Q39174244 | Insulin-like growth-factor-1-induced PKB signaling and Egr-1 expression is inhibited by curcumin in A-10 vascular smooth muscle cells |
Q35103987 | Leukotriene-C4 synthase, a critical enzyme in the activation of store-independent Orai1/Orai3 channels, is required for neointimal hyperplasia |
Q30557273 | Microsomal prostaglandin e2 synthase-1 modulates the response to vascular injury |
Q37361545 | PPARγ modulates vascular smooth muscle cell phenotype via a protein kinase G-dependent pathway and reduces neointimal hyperplasia after vascular injury |
Q28478187 | Peroxisome proliferator-activated receptor-gamma agonists suppress tissue factor overexpression in rat balloon injury model with paclitaxel infusion |
Q34389006 | Pharmacological modulation by celecoxib of cachexia associated with experimental arthritis and atherosclerosis in rabbits |
Q33744563 | Receptor interacting protein 3 suppresses vascular smooth muscle cell growth by inhibition of the phosphoinositide 3-kinase-Akt axis |
Q36797387 | Role of COX-2-derived PGE2 on vascular stiffness and function in hypertension |
Q30475246 | Study of vascular injuries using endothelial denudation model and the therapeutic application of shock wave: a review. |
Q45962157 | Sulfasalazine induces haem oxygenase-1 via ROS-dependent Nrf2 signalling, leading to control of neointimal hyperplasia. |
Q53410809 | Tauroursodeoxycholate (TUDCA) inhibits neointimal hyperplasia by suppression of ERK via PKCα-mediated MKP-1 induction. |
Q104135011 | The antiplatelet agent revacept prevents the increase of systemic thromboxane A2 biosynthesis and neointima hyperplasia |
Q36419349 | The effects of a cyclooxygenase-2 (COX-2) expression and inhibition on human uveal melanoma cell proliferation and macrophage nitric oxide production |
Q38637342 | The protective effect of bee venom on fibrosis causing inflammatory diseases |
Q42012970 | Utilization of thin film method for preparation of celecoxib loaded liposomes. |
Search more.